138 related articles for article (PubMed ID: 37935428)
1. Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
Chen L; Rangel JDG; Cil T; Li X; Cicin I; Shen Y; Liu Z; Ozyilkan O; Igor B; Chen J; Oleksandr K; Chen Z; Zhang H; Fu Z; Dong Q; Song S; Yu JC; Zhang L
Cancer Med; 2023 Nov; 12(22):20847-20863. PubMed ID: 37935428
[TBL] [Abstract][Full Text] [Related]
2. PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin
Reinmuth N; Bryl M; Bondarenko I; Syrigos K; Vladimirov V; Zereu M; Bair AH; Hilton F; Liau K; Kasahara K
BioDrugs; 2019 Oct; 33(5):555-570. PubMed ID: 31338773
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
Trukhin D; Poddubskaya E; Andric Z; Makharadze T; Bellala RS; Charoentum C; Yañez Ruiz EP; Fulop A; Hyder Ali IA; Syrigos K; Katgi N; Lopez Chuken YA; Rumyana I; Reyes-Igama J; Costamilan RC; Del Campo García A; Florez A; Paravisini A; Millan S;
BioDrugs; 2021 Jul; 35(4):429-444. PubMed ID: 33914256
[TBL] [Abstract][Full Text] [Related]
4. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
[TBL] [Abstract][Full Text] [Related]
5. Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.
Verschraegen C; Andric Z; Moiseenko F; Makharadze T; Shevnya S; Oleksiienko A; Yañez Ruiz E; Kim S; Ahn K; Park T; Park S; Ju H; Ohe Y
BioDrugs; 2022 Nov; 36(6):749-760. PubMed ID: 36169807
[TBL] [Abstract][Full Text] [Related]
6. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.
Stroyakovskiy DL; Fadeeva NV; Matrosova MP; Shelepen KG; Adamchuk GA; Roy B; Nagarkar R; Kalloli M; Zhuravleva D; Voevodin GD; Shustova MS; Kryukov F
BMC Cancer; 2022 Feb; 22(1):129. PubMed ID: 35105329
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab biosimilar candidate TAB008 compared to Avastin
Lu S; Qin S; Zhou Z; Chen J; Gu K; Sun P; Pan Y; Yu G; Ma K; Shi J; Sun Y; Yang L; Chen P; Liu A; He J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5907-5914. PubMed ID: 36595042
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Shi Y; Lei K; Jia Y; Ni B; He Z; Bi M; Wang X; Shi J; Zhou M; Sun Q; Wang G; Chen D; Shu Y; Liu L; Guo Z; Liu Y; Yang J; Wang K; Xiao K; Wu L; Yi T; Sun D; Kang M; Ma T; Mao Y; Shi J; Tang T; Wang Y; Xing P; Lv D; Liao W; Luo Z; Wang B; Wu X; Zhu X; Han S; Guo Q; Liu R; Lu Z; Zhang J; Fang J; Hu C; Ji Y; Liu G; Lu H; Wu D; Zhang J; Zhu S; Liu Z; Qiu W; Ye F; Yu Y; Zhao Y; Zheng Q; Chen J; Pan Z; Zhang Y; Lian W; Jiang B; Qiu B; Zhang G; Zhang H; Chen Y; Chen Y; Duan H; Li M; Liu S; Ma L; Pan H; Yuan X; Yuan X; Zheng Y; Gao E; Zhao L; Wang S; Wu C
Cancer Commun (Lond); 2021 Sep; 41(9):889-903. PubMed ID: 34184418
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
Syrigos K; Abert I; Andric Z; Bondarenko IN; Dvorkin M; Galic K; Galiulin R; Kuchava V; Sriuranpong V; Trukhin D; Zhavrid E; Fu D; Kassalow LM; Jones S; Bashir Z;
BioDrugs; 2021 Jul; 35(4):417-428. PubMed ID: 34264503
[TBL] [Abstract][Full Text] [Related]
10. A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer.
Reck M; Luft A; Bondarenko I; Shevnia S; Trukhin D; Kovalenko NV; Vacharadze K; Andrea F; Hontsa A; Choi J; Shin D
Lung Cancer; 2020 Aug; 146():12-18. PubMed ID: 32502923
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.
Thatcher N; Goldschmidt JH; Thomas M; Schenker M; Pan Z; Paz-Ares Rodriguez L; Breder V; Ostoros G; Hanes V
Clin Cancer Res; 2019 Apr; 25(7):2088-2095. PubMed ID: 30617139
[TBL] [Abstract][Full Text] [Related]
12. Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer.
Socinski MA; Waller CF; Idris T; Bondarenko I; Luft A; Beckmann K; Vishweswaramurthy A; Loganathan S; Donnelly C; Hummel MA; Shapiro R; Woods M; Rao A; Nayak VG; Ranganna G; Barve A
Ther Adv Med Oncol; 2021; 13():17588359211045845. PubMed ID: 34819997
[TBL] [Abstract][Full Text] [Related]
13. Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab.
Cao D; Deng C; Wang G; Mei X; Xie J; Liu Y; Liu Y; Yang Y; Li S; Liu C
Drugs R D; 2023 Sep; 23(3):267-288. PubMed ID: 37479945
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M
Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.
Sugawara S; Lee JS; Kang JH; Kim HR; Inui N; Hida T; Lee KH; Yoshida T; Tanaka H; Yang CT; Nishio M; Ohe Y; Tamura T; Yamamoto N; Yu CJ; Akamatsu H; Namba Y; Sumiyoshi N; Nakagawa K
Ann Oncol; 2021 Sep; 32(9):1137-1147. PubMed ID: 34139272
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin
Li CSW; Sweeney K; Cronenberger C
Cancer Chemother Pharmacol; 2020 Mar; 85(3):487-499. PubMed ID: 31768697
[TBL] [Abstract][Full Text] [Related]
17. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
[TBL] [Abstract][Full Text] [Related]
18. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Spigel DR; Patel JD; Reynolds CH; Garon EB; Hermann RC; Govindan R; Olsen MR; Winfree KB; Chen J; Liu J; Guba SC; Socinski MA; Bonomi P
J Thorac Oncol; 2015 Feb; 10(2):353-9. PubMed ID: 25611228
[TBL] [Abstract][Full Text] [Related]
19. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
Blumenschein GR; Kabbinavar F; Menon H; Mok TSK; Stephenson J; Beck JT; Lakshmaiah K; Reckamp K; Hei YJ; Kracht K; Sun YN; Sikorski R; Schwartzberg L;
Ann Oncol; 2011 Sep; 22(9):2057-2067. PubMed ID: 21321086
[TBL] [Abstract][Full Text] [Related]
20. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD; Bonomi P; Socinski MA; Govindan R; Hong S; Obasaju C; Pennella EJ; Girvan AC; Guba SC
Clin Lung Cancer; 2009 Jul; 10(4):252-6. PubMed ID: 19632943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
